Cargando…

Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100

Toll-like receptor (TLR) 3 agonists emerged as attractive candidates for vaccination strategies against tumors and pathogens. An important mechanism of action of such agonists is based on the activation of TLR3-expressing dendritic cells (DCs), which display a unique capacity to induce and stimulate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naumann, Kai, Wehner, Rebekka, Schwarze, Anett, Petzold, Christiane, Schmitz, Marc, Rohayem, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878805/ https://www.ncbi.nlm.nih.gov/pubmed/24454470 http://dx.doi.org/10.1155/2013/283649

Ejemplares similares

TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
por: Komal, Asma, et al.
Publicado: (2021)

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation
por: Peng, Paul, et al.
Publicado: (2015)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Efficiency of Interferon-γ in Activating Dendritic Cells and Its Potential Synergy with Toll-like Receptor Agonists
por: Bian, Yuanzhi, et al.
Publicado: (2023)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
por: Vo, Manh-Cuong, et al.
Publicado: (2015)

The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells
por: Guo, Xueheng, et al.
Publicado: (2017)

Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
por: He, Mi, et al.
Publicado: (2022)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists
por: Shey, Muki S., et al.
Publicado: (2016)

Synergy between Vitamin D(3) and Toll-Like Receptor Agonists Regulates Human Dendritic Cell Response during Maturation
por: Brosbøl-Ravnborg, Anne, et al.
Publicado: (2013)

Characterization of the cytokine and maturation responses of pure populations of porcine plasmacytoid dendritic cells to porcine viruses and toll-like receptor agonists
por: Calzada-Nova, Gabriela, et al.
Publicado: (2010)

Differential modulation of cysteinyl leukotriene receptor 1 and 2 expression by distinct Toll-like receptor agonists in monocyte-derived dendritic cells
por: Rola-Pleszczynski, M, et al.
Publicado: (2004)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
por: Li, Wei, et al.
Publicado: (2022)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
por: Lövgren, Tanja, et al.
Publicado: (2017)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Dendritic Cell-Based Immunotherapy for Prostate Cancer
por: Jähnisch, Hanka, et al.
Publicado: (2010)

Toll‐like receptors matter: plasmacytoid dendritic cells in COVID‐19
por: Becker, Jennifer, et al.
Publicado: (2022)

Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist
por: Hu, Zhiqiang, et al.
Publicado: (2013)

Src Kinases Are Required for a Balanced Production of IL-12/IL-23 in Human Dendritic Cells Activated by Toll-Like Receptor Agonists
por: Kuka, Mirela, et al.
Publicado: (2010)

Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8(+) T cells
por: Park, Sung Nam, et al.
Publicado: (2013)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
por: Christopher, ME, et al.
Publicado: (2011)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

The functional and inflammatory response of brain endothelial cells to Toll-Like Receptor agonists
por: Johnson, Rebecca H., et al.
Publicado: (2018)

Toll-Like Receptor Agonists Modulate Wound Regeneration in Airway Epithelial Cells
por: Lewandowska-Polak, Anna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p2h79mcnr95mehbiapbl0bs6iq